{
    "root": "695c03ee-2c4f-44a7-aaca-bb41fdaa9dca",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Qfitlia",
    "value": "20250326",
    "ingredients": [
        {
            "name": "FITUSIRAN",
            "code": "SV9W47ZLE1"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
            "code": "70WT22SF4B"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors.",
    "contraindications": "For subcutaneous use only. Starting dose: 50 mg once every 2 months ( 2.1 ). Monitor AT activity using an FDA-cleared test. Maintain AT activity between 15â€“35% by adjusting the dose and/or frequency of administration ( 2.2 ). See Full Prescribing Information for important preparation and administration instructions ( 2.4 ).",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}